Moclobemide-mianserine

From Psychiatrienet
Revision as of 10:55, 6 May 2009 by Alexandra (talk | contribs) (Created page with '{{Drugswitch | from = moclobemide | to = mianserine | stop = * Gradually reduce dosage of moclobemide to a maximum of 300 mg/ day. * When a dosage of 300 mg/day is reached, ...')
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide
Mianserine
Type Antidepressant
Group other
links
PubChem 4184
PubMed Mianserine
Kompas (Dutch) Mianserine
Wikipedia Mianserine

Switch medication from moclobemide to mianserine.[1] [2]

Nietinrijdenbord.png Stop moclobemide
  • Gradually reduce dosage of moclobemide to a maximum of 300 mg/ day.
  • When a dosage of 300 mg/day is reached, stop administration.
Eenrichtingbord.png Start mianserine
  • Day 1-2: a wash-out period of two days is necessary.
  • Day 3: start mianserine after this period in a low dosage of 30 mg/day.


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.